Cargando…

Absence of prostate oedema obviates the need for delay between fiducial marker insertion and radiotherapy simulation

INTRODUCTION: Fiducial markers (FMs) are commonly inserted into the prostate for image guided radiation therapy. This study aimed to quantify prostate oedema immediately following FM insertion compared to prostate volumes measured a week later, at the time of simulation for radiation therapy. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Deepti, Tan, Alex, Brown, Amy, Pain, Tilley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753875/
https://www.ncbi.nlm.nih.gov/pubmed/32614152
http://dx.doi.org/10.1002/jmrs.412
_version_ 1783626076956655616
author Patel, Deepti
Tan, Alex
Brown, Amy
Pain, Tilley
author_facet Patel, Deepti
Tan, Alex
Brown, Amy
Pain, Tilley
author_sort Patel, Deepti
collection PubMed
description INTRODUCTION: Fiducial markers (FMs) are commonly inserted into the prostate for image guided radiation therapy. This study aimed to quantify prostate oedema immediately following FM insertion compared to prostate volumes measured a week later, at the time of simulation for radiation therapy. METHODS: Thirty patients underwent a verification computed tomography (VCT) scan in treatment position immediately after the fiducial insertion and their planning computed tomography scan (PCT) one week after. Patient data sets were retrospectively evaluated, comparing prostate volumes and planning target volumes (PTV). Volumes were delineated by a single radiation oncologist, blinded to whether the scan was VCT or PCT. Distances between the FMs were measured on both scans. Descriptive statistics described the data, DICE similarity co‐efficient (DSC) calculated, and paired t‐tests were used to compare paired data. RESULTS: The median prostate volume was 35.09 cc and 36.31 cc for VCT and PCT data sets, respectively, and median PTV was 118.56 cc and 127.04 cc for VCT and PCT, respectively. There was no significant difference in prostate volumes (P = 0.3037) or PTV (P = 0.1279), with a DSC of 0.87 (range 0.76–0.91) and 0.91 (range 0.85 to 0.95), respectively. Similarly, there was no significant difference in distance between fiducial markers (P > 0.05). CONCLUSION: This study demonstrates no statistically significant difference in prostate or PTV volumes (P > 0.05) between the CT acquired at fiducial marker insertion compared with the CT acquired a week later. Therefore, oedema is not significant enough to justify a delay between FM insertion and simulation.
format Online
Article
Text
id pubmed-7753875
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77538752020-12-23 Absence of prostate oedema obviates the need for delay between fiducial marker insertion and radiotherapy simulation Patel, Deepti Tan, Alex Brown, Amy Pain, Tilley J Med Radiat Sci Original Articles INTRODUCTION: Fiducial markers (FMs) are commonly inserted into the prostate for image guided radiation therapy. This study aimed to quantify prostate oedema immediately following FM insertion compared to prostate volumes measured a week later, at the time of simulation for radiation therapy. METHODS: Thirty patients underwent a verification computed tomography (VCT) scan in treatment position immediately after the fiducial insertion and their planning computed tomography scan (PCT) one week after. Patient data sets were retrospectively evaluated, comparing prostate volumes and planning target volumes (PTV). Volumes were delineated by a single radiation oncologist, blinded to whether the scan was VCT or PCT. Distances between the FMs were measured on both scans. Descriptive statistics described the data, DICE similarity co‐efficient (DSC) calculated, and paired t‐tests were used to compare paired data. RESULTS: The median prostate volume was 35.09 cc and 36.31 cc for VCT and PCT data sets, respectively, and median PTV was 118.56 cc and 127.04 cc for VCT and PCT, respectively. There was no significant difference in prostate volumes (P = 0.3037) or PTV (P = 0.1279), with a DSC of 0.87 (range 0.76–0.91) and 0.91 (range 0.85 to 0.95), respectively. Similarly, there was no significant difference in distance between fiducial markers (P > 0.05). CONCLUSION: This study demonstrates no statistically significant difference in prostate or PTV volumes (P > 0.05) between the CT acquired at fiducial marker insertion compared with the CT acquired a week later. Therefore, oedema is not significant enough to justify a delay between FM insertion and simulation. John Wiley and Sons Inc. 2020-07-02 2020-12 /pmc/articles/PMC7753875/ /pubmed/32614152 http://dx.doi.org/10.1002/jmrs.412 Text en © 2020 The Authors. Journal of Medical Radiation Sciences published by John Wiley & Sons Australia, Ltd on behalf of Australian Society of Medical Imaging and Radiation Therapy and New Zealand Institute of Medical Radiation Technology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Patel, Deepti
Tan, Alex
Brown, Amy
Pain, Tilley
Absence of prostate oedema obviates the need for delay between fiducial marker insertion and radiotherapy simulation
title Absence of prostate oedema obviates the need for delay between fiducial marker insertion and radiotherapy simulation
title_full Absence of prostate oedema obviates the need for delay between fiducial marker insertion and radiotherapy simulation
title_fullStr Absence of prostate oedema obviates the need for delay between fiducial marker insertion and radiotherapy simulation
title_full_unstemmed Absence of prostate oedema obviates the need for delay between fiducial marker insertion and radiotherapy simulation
title_short Absence of prostate oedema obviates the need for delay between fiducial marker insertion and radiotherapy simulation
title_sort absence of prostate oedema obviates the need for delay between fiducial marker insertion and radiotherapy simulation
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7753875/
https://www.ncbi.nlm.nih.gov/pubmed/32614152
http://dx.doi.org/10.1002/jmrs.412
work_keys_str_mv AT pateldeepti absenceofprostateoedemaobviatestheneedfordelaybetweenfiducialmarkerinsertionandradiotherapysimulation
AT tanalex absenceofprostateoedemaobviatestheneedfordelaybetweenfiducialmarkerinsertionandradiotherapysimulation
AT brownamy absenceofprostateoedemaobviatestheneedfordelaybetweenfiducialmarkerinsertionandradiotherapysimulation
AT paintilley absenceofprostateoedemaobviatestheneedfordelaybetweenfiducialmarkerinsertionandradiotherapysimulation